Syra Health Seeks Shareholder Approval for 34% Equity Incentive Plan Increase
SYRA has more than doubled off its 52-week low of $0.052 on light trading volume (0.1× avg).
Summary
Syra Health Corp. filed definitive proxy materials for its annual meeting, seeking shareholder approval to significantly increase its equity incentive plan by 4.1 million shares, representing a potential dilution of over 34%.
Key Events · Corporate Governance and Compliance · SYRA
-
Annual Meeting Scheduled
The Annual Meeting of Stockholders is scheduled for July 23, 2026, to consider several proposals.
-
Significant Equity Plan Increase Proposed
Shareholders will vote on amending the 2022 Omnibus Equity Incentive Plan to increase the number of Class A shares available for issuance to 4,100,000. This represents a potential dilution of approximately 34.3% of current outstanding shares.
-
Director Elections
Shareholders will vote on the election of five directors to the Board.
-
Auditor Ratification
The appointment of M&K CPAS, PLLC as the independent registered public accounting firm for fiscal year 2026 will be put to a shareholder vote.
Analysis · SYRA · Trade & Services
Syra Health Corp. is asking shareholders to approve a significant increase in its equity incentive plan, adding 4.1 million Class A shares. This represents a potential dilution of over 34% of the company's current outstanding shares. For a micro-cap company that recently achieved its first profitable quarter but previously faced 'going concern' doubts, such a substantial authorization for future share issuance creates a significant overhang and could impact shareholder value through dilution, even if it provides flexibility for compensation or future capital needs.
At the time of this filing, SYRA was trading at $0.50 on OTC in the Trade & Services sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.05 to $0.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.